Assessment of Disease Severity and Activity in Inflammatory Bowel Disease

References

• Singleton JW. Laboratory investigations and disease activity in inflammatory bowel disease. Inflammatory bowel disease, R N Allan, M RB Keighley, J Alexander-Williams, C Hawkins. Churchill Livingstone, Edinburgh 1990; 199–206
   Google Scholar
• Singleton JW. Clinical activity assessment in inflammatory bowel disease. Dig Dis Sci 1987; 32: 42s–5s
   PubMedGoogle Scholar
• de Dombal FT. Measuring and quantifying the status of patients with inflammatory bowel disease. Inflammatory bowel disease. Some international reflections. Oxford University Press, Oxford 1986; 267–85
   Google Scholar
• Binder V. A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa, and cytologic picture of mucosal exudate in ulcerative colitis. Scand J Gastroenterol 1970; 5: 627–32
   PubMed Web of Science ®Google Scholar
• Riddell RH. Pathology of idiopathic inflammatory bowel disease. Inflammatory bowel disease.3rd ed., J B Kirsner, R G Shorter. Lea & Febiger, Philadelphia 1988; 329–50
   Google Scholar
• Beck IT. Laboratory assessment of inflammatory bowel disease. Dig Dis Sci 1987; 32: 26s–41s
   PubMedGoogle Scholar
• Gomes P, Du Boulay C, Smith C L, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27: 92–5
   PubMed Web of Science ®Google Scholar
• Baron J H, Connell A M, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964; 1: 89–92
   PubMed Web of Science ®Google Scholar
• Watts JMcK, Thompson H, Goligher JC. Sigmoidoscopy and cytology in the detection of microscopic disease of the rectal mucosa in ulcerative colitis. Gut 1966; 7: 288–94
   PubMed Web of Science ®Google Scholar
• Holmquist L, Åhrén C, Fällström SP. Clinical disease activity and inflammatory activity in the rectum in relation to mucosal inflammation assessed by colonoscopy. A study of children and adolescents with chronic inflammatory bowel disease. Acta Paediatr Scand 1990; 79: 527–34
   PubMedGoogle Scholar
• Truelove S C, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; 2: 1041–8
   PubMed Web of Science ®Google Scholar
• Garrett J W, Drossman DA. Health status in inflammatory bowel disease. Biological and behavioral considerations. Gastroenterology 1990; 99: 90–6
   PubMed Web of Science ®Google Scholar
• Jewell D P, Caprilli R, Mortensen N, Nicholls R J, Wright JP. Indications and timing of surgery for severe ulcerative colitis. Gastroenterol Int 1991; 4: 161–4
   Google Scholar
• Powell-Tuck J, Bown R L, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978; 13: 833–7
   PubMed Web of Science ®Google Scholar
• Danovitch SH. Fulminant colitis and toxic megacolon. Gastroenterol Clin North Am 1989; 18: 73–82
   PubMed Web of Science ®Google Scholar
• Gallagher N D, Goulston J M, Wyndham N, Morrow W. The management of fulminant ulcerative colitis. Gut 1962; 3: 306–11
   PubMedGoogle Scholar
• Campieri M, Gionchetti P, Belluzzi A, et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 1991; 32: 929–31
   PubMed Web of Science ®Google Scholar
• Riley S A, Mani V, Goodman M J, Herd M E, Dutt S, Turnburg LA. Comparison of delayed-release 5 aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94: 1383–9
   PubMedGoogle Scholar
• Riley S A, Mani V, Goodman M J, Herd M E, Dutt S, Turnberg LA. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988; 29: 669–74
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D. on behalf of an international study group. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989; 298: 82–6
   PubMed Web of Science ®Google Scholar
• Sninsky C A, Cort D H, Shanahan F, et al. Oral mesalasine (asacol) for mildly to moderately active ulcerative colitis. Ann Intern Med 1991; 115: 350–5
   PubMed Web of Science ®Google Scholar
• Schroeder K W, Tremaine W J, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987; 317: 1625–9
   PubMed Web of Science ®Google Scholar
• Maier K, v Gaisberg U, Kraus B. Colitis ulcerosa: aktivitätsindex zur klinischen und histologischen klassifikation der entzündungsaktivität. Schweiz Med Wochenschr 1988; 118: 763–6
   PubMedGoogle Scholar
• Dearing W H, McGuckin W F, Elveback LR. Serum α1acid glycoprotein in chronic ulcerative colitis. Gastroenterology 1969; 56: 295–303
   PubMed Web of Science ®Google Scholar
• Rutegård I, Åhsgren L, Stenling R, Nilsson T. A simple index for assessment of disease activity in patients with ulcerative colitis. Hepatogastroenterology 1990; 37: 110–2
   PubMedGoogle Scholar
• Lennard-Jones J E, Ritchie J K, Hilder W, Spicer CC. Assessment of severity in colitis: a preliminary study. Gut 1975; 16: 579–84
   PubMed Web of Science ®Google Scholar
• Meyers S, Lerer P K, Feuer E J, Johnson J W, Janowitz HD. Predicting the outcome of corticoid therapy for acute ulcerative colitis. J Clin Gastroenterol 1987; 9: 50–4
   PubMed Web of Science ®Google Scholar
• Edwards F C, Truelove SC. The course and prognosis of ulcerative colitis. Gut 1963; 4: 299–315
   PubMed Web of Science ®Google Scholar
• Oshitani N, Kitano A, Fukushima R, et al. Predictive factors for the response of ulcerative colitis patients during the acute phase treatment. Digestion 1990; 46: 107–13
   PubMedGoogle Scholar
• Olaison G, Sjödahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990; 31: 325–8
   PubMed Web of Science ®Google Scholar
• Modigliani R, Mary J-Y, Simon J-F, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Gastroenterology 1990; 98: 811–8
   PubMed Web of Science ®Google Scholar
• Ferguson R, Allan R N, Cooke WT. A study of cellular infiltrate of the proximal jejunal mucosa in ulcerative colitis and Crohn's disease. Gut 1975; 16: 205–8
   PubMed Web of Science ®Google Scholar
• Surawicz C M, Meisel J L, Ylvisaker T, Saunders D R, Rubin CE. Rectal biopsy in the diagnosis of Crohn's disease: value of multiple biopsies and serial sectioning. Gastroenterology 1981; 81: 66–71
   Google Scholar
• Korelitz B I, Sommers S. Rectal biopsy in patients with Crohn's disease. Normal mucosa on sigmoidoscopic examination. JAMA 1977; 237: 2742–4
   PubMed Web of Science ®Google Scholar
• Goodman M J, Skinner J M, Truelove SC. Abnormalities in the apparently normal bowel mucosa in Crohn's disease. Lancet 1976; 1: 275–8
   PubMed Web of Science ®Google Scholar
• de Dombal F T, Burton I L, Clamp S E, Goligher JC. Short-term course and prognosis of Crohn's disease. Gut 1974; 15: 435–43
   PubMed Web of Science ®Google Scholar
• Hodgson H JF. Assessment of drug therapy in inflammatory bowel disease. Br J Clin Pharmacol 1982; 14: 159–70
   PubMedGoogle Scholar
• Best W R, Becktel J M, Singleton J W, Kern F. Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 1976; 70: 439–44
   PubMed Web of Science ®Google Scholar
• Mee A S, Brown D J, Jewell DP. Crohn's disease activity index—is it useful? [abstract]. Gut 1978; 19a: 990
   Google Scholar
• André C, Descos L, Landais P, Fermanian J. Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. Gut 1981; 22: 571–4
   PubMed Web of Science ®Google Scholar
• Harvey R F, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; 1: 514
   PubMed Web of Science ®Google Scholar
• Myren J, Bouchier I AD, Watkinson G, Sofley A, Clamp S E, de Dombal FT. The O.M.G.E. multinational inflammatory bowel disease survey 1976–1982. A further report on 2,657 cases. Scand J Gastroenterol 1984; 19: 1–27, Suppl 95
   PubMed Web of Science ®Google Scholar
• Van Hees P AM, Van Elteren P H, Van Lier H JJ, Van Tongeren J HM. An index of inflammatory activity in patients with Crohn's disease. Gut 1980; 21: 279–86
   PubMed Web of Science ®Google Scholar
• Present D H, Korelitz B I, Wisch N, Glass J L, Sachar D B, Pasternack BS. Treatment of Crohn's disease with 6-mer-captopurine: a long-term randomized, double-blind study. N Engl J Med 1981; 302: 981–7
   Google Scholar
• Sandler R S, Jordan M C, Kupper LL. Development of a Crohn's index for survey research. J Clin Epidemiol 1988; 41: 451–8
   PubMed Web of Science ®Google Scholar
• de Dombal F T, Softley A. IOIBD report no. 1: observer variation in calculating indices of severity and activity in Crohn's disease. Gut 1987; 28: 474–81
   PubMed Web of Science ®Google Scholar
• Brooke BN. Index of Crohn's disease activity. Lancet 1980; 1: 711
   PubMedGoogle Scholar
• Tvede M, Bondesen S, Nielsen H O, Rasmussen SN. Serum antibodies to bacteroides species in chronic inflammatory bowel disease. Scand J Gastroenterol 1983; 18: 783–9
   PubMed Web of Science ®Google Scholar
• Goebell H, Wienbeck M, Schomerus H, Malchow H. Evaluation of the Crohn's disease activity index (CDAI) and the Dutch index for severity and activity of Crohn's disease. An analysis of the data from the European Cooperative Crohn's Disease Study. Med Klin 1990; 85: 573–6
   PubMedGoogle Scholar
• Drossman D A, Leserman J., Mitchell C M, Li Z, Zagami E A, Patrick DL. Health status and health care use in persons with inflammatory bowel disease. A national sample. Dig Dis Sci 1991; 36: 1746–55
   PubMed Web of Science ®Google Scholar
• Drossman D A, Patrick D L, Mitchell C M, Zagami E A, Appelbaum Ml. Health-related quality of life in inflammatory bowel disease: functional status and patient worries and concerns. Dig Dis Sci 1989; 34: 1379–86
   PubMed Web of Science ®Google Scholar
• International Committee for Standardization in Haematology (Expert Panel on Blood Rheology). Guidelines on selection of laboratory tests for monitoring the acute phase. J Clin Pathol 1988; 41: 1203–12
   PubMed Web of Science ®Google Scholar
• André C, Descos L, André F, Vignal J, Landais P, Fermanian J. Biological measurements of Crohn's disease activity—a reassessment. Hepatogastroenterology 1985; 3232: 135–7
   Google Scholar
• Fagan E A, Dyck R F, Maton P N, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982; 12: 351–9
   PubMed Web of Science ®Google Scholar
• Jensen K B, Jarnum S, Koudahl G, Kristensen M. Serum orosomucoid in ulcerative colitis. Its relation to clinical activity, protein loss, and turnover of albumin and IgG. Scand J Gastroenterol 1976; 11: 177–83
   PubMedGoogle Scholar
• Talstadt I, Gjone E. The disease activity of ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1976; 11: 403–8
   PubMedGoogle Scholar
• Sachar D B, Luppescu N E, Bodian C, Shlien R D, Fabry T L, Gumaste VV. Erytrocyte sedimentation as a measure of Crohn's disease activity: opposite trends in ileitis versus colitis. J Clin Gastroenterol 1990; 12: 643–6
   PubMedGoogle Scholar
• Harries A D, Fitzsimons E, Fifleld R, Dew M J, Rhodes J. Platelet count: a simple measure of activity in Crohn's disease. Br Med J 1983; 286: 1476
   PubMedGoogle Scholar
• Pepys MB. Serum C-reactive protein, serum amyloid P-component and serum amyloid A protein in autoimmune disease. Autoimmunity: clinics in immunology and allergy, E J Holborow. WB Saunders, Eastbourne 1981; 77–101
   Google Scholar
• Dinarello CA. Interleukin-1. Dig Dis Sci 1988; 33: 25s–35s
   Google Scholar
• Weeke B, Jarnum S. Serum concentrations of 19 serum proteins in Crohn's disease and ulcerative colitis. Gut 1971; 12: 297–302
   PubMed Web of Science ®Google Scholar
• Marner I-L, Friborg S, Simonsen E. Disease activity and serum proteins in ulcerative colitis. Immunochemical quantitation. Scand J Gastroenterol 1975; 10: 537–44
   PubMed Web of Science ®Google Scholar
• Nielsen H, Petersen P H, Svehag S-E. Circulating immune complexes in ulcerative colitis. II. Correlation with serum protein concentrations and complement conversion products. Clin Exp Immunol 1978; 31: 81–91
   PubMed Web of Science ®Google Scholar
• Brignola C, Lanfranchi G A, Campieri M, et al. Importance of laboratory parameters in the evaluation of Crohn's disease activity. J Clin Gastroenterol 1986; 8: 245–8
   PubMed Web of Science ®Google Scholar
• Meryn S, Lochs H, Bettelheim P, Sertl K, Mulak K. Serum-proteinkonzentrationen—Parameter für die Krankheitsaktivität bei Morbus Crohn?. Leber Magen Darm 1985; 15: 160–4
   PubMedGoogle Scholar
• Lubega J, Davies J. A comparison of serum mucoprotein with serum or, acid glycoprotein, haptoglobin and α1 antitrypsin assays in monitoring inflammatory bowel disease. Clin Chim Acta 1990; 188: 59–70
   PubMedGoogle Scholar
• Pepys MB. C-reactive protein fifty years on. Lancet 1981; 1: 653–6
   PubMed Web of Science ®Google Scholar
• Kindmark CO. Sequential changes in plasma proteins in various acute diseases. Plasma protein turnover, R G Bianchi, M MacFarlane. MacMillan, London 1976; 395–402
   Google Scholar
• Shine B, Berghouse L, Lennard-Jones J E, Landon J. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 1985; 148: 105–9
   PubMed Web of Science ®Google Scholar
• Aronsen K-F, Ekelund G, Kindmark C-O, Laurell C-B. Sequential changes of plasma proteins after surgical trauma. Scand J Clin Lab Invest 1972; 29: 127–36, Suppl 124
   Web of Science ®Google Scholar
• Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. J Clin Gastroenterol 1988; 10: 401–5
   PubMed Web of Science ®Google Scholar
• Buckell N A, Lennard-Jones J E, Hernandez M A, Kohn J, Riches P G, Wadsworth J. Measurements of serum proteins during attacks of ulcerative colitis as a guide to patient management. Gut 1979; 20: 22–7
   PubMedGoogle Scholar
• Pepys M B, Dash A C, Markman R E, Thomas H C, Williams B D, Petrie A. Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol 1978; 32: 119–24
   PubMed Web of Science ®Google Scholar
• Saverymuttu S H, Hodgson H JF, Chadwick V S, Pepys MB. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986; 27: 809–13
   PubMed Web of Science ®Google Scholar
• Mazlam M Z, Hodgson H JF. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992; 33: 773–8
   PubMed Web of Science ®Google Scholar
• Prantera C, Luzi C, Olivotto P, Levenstein S, Cerro P, Fanucci A. Relationship between clinical and laboratory parameters and length of lesion in Crohn's disease of small bowel. Dig Dis Sci 1991; 29: 1093–7
   Google Scholar
• Adeyemi E O, Hodgson H JF. Lactoferrin: a correlate of disease activity in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1991; 3: 51–6
   Google Scholar
• Groos V, Andus T, Cäsar I, et al. Granulocyte elastase in plasma and faeces as a marker of disease activity in patients with inflammatory bowel disease [abstract]. Gastroenterology 1991; 100: a583
   PubMedGoogle Scholar
• Adeyemi E O, Neumann S, Chadwick VS., Hodgson H JF, Pepys MB. Circulating human leucocyte elastase in patients with inflammatory bowel disease. Gut 1985; 26: 1306–11
   PubMed Web of Science ®Google Scholar
• Reibnegger G, Bollach R, Fuchs D, et al. A simple index relating clinical activity in Crohn's disease with T cell activation: hematocrit, frequency of liquid stools and urinary neopterin as parameters. Immunobiol 1986; 173: 1–11
   PubMed Web of Science ®Google Scholar
• Niederwieser D, Fuchs D, Hausen A, et al. Neopterin as new biochemical marker in the clinical assessment of ulcerative colitis. Immunobiology 1985; 170: 320–6
   PubMed Web of Science ®Google Scholar
• Klass H J, Neale G. Serum and faecal lysozyme in inflammatory bowel disease. Gut 1978; 19: 233–9
   PubMed Web of Science ®Google Scholar
• Falchuk K R, Perrotto J L, Isselbacher JK. Serum lysozyme in Crohn's disease. A useful index of disease activity. Gastroenterology 1975; 69: 893–6
   PubMedGoogle Scholar
• Kane S P, Hoffbrand A V, Neale G. Indices of granulocyte activity in inflammatory bowel disease. Gut 1974; 15: 953–9
   PubMed Web of Science ®Google Scholar
• Brynskov J, Tvede N. Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin. Gut 1990; 31: 795–9
   PubMed Web of Science ®Google Scholar
• Crabtree J E, Juby L D, Heatley R V, Lobo A J, Bullimore D W, Axon A TR. Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentration to disease activity. Gut 1190; 31: 1033–6
   Google Scholar
• Williams A JK, Symons J A, Wachet K, Heading R C, Duff GW. Serum soluble interleukin-2 receptor: the best indicator of activity in Crohn's disease [abstract]. Gastroenterology 1991; 100: a262
   Google Scholar
• Ch Mueller, Knoflach P, Zielinski CC. T-cell activation in Crohn's disease. Increased levels of soluble interleukin-2 receptor in serum and in supernatant of stimulated peripheral blood mononuclear cells. Gastroenterology 1990; 98: 639–46
   PubMedGoogle Scholar
• Gross V, Andus T, Caesar I, Roth M, Schölmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992; 102: 514–9
   PubMed Web of Science ®Google Scholar
• Mahida Y R, Kurlac L, Gallagher A, Hawkey CJ. High circulating concentrations of interleukin-6 in active Crohn's disease but not in ulcerative colitis. Gut 1991; 32: 1531–4
   PubMed Web of Science ®Google Scholar
• Lobo A J, Evans S W, Jones S C, et al. Plasma interleukin-6 in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1992; 4: 367–72
   Web of Science ®Google Scholar
• Ward M, Eastwood MA. Serum C3 and C4 complement components in ulcerative colitis and Crohn's disease. Digestion 1975; 13: 100–3
   PubMed Web of Science ®Google Scholar
• Elson CE. The immunology of inflammatory bowel disease. Inflammatory bowel disease.3rd ed., J B Kirsner, R G Shorter. Lea & Febiger, Philadelphia 1988; 97–164
   Google Scholar
• Feinstein P A, Kaplan S R, Thayer WR. The alternate complement pathway in inflammatory bowel disease. Quantitation of the C3 proactivator (factor B) protein. Gastroenterology 1976; 70: 181–5
   PubMed Web of Science ®Google Scholar
• Hodgson H JF, Potter B J, Jewell DP. Humoral immune system in inflammatory bowel disease. I. Complement levels. Gut 1977; 18: 749–53
   PubMed Web of Science ®Google Scholar
• Elmgreen J, Berkowicz A, Sørensen H. Hypercatabolism of complement in Crohn's disease—assessment of circulating C3c. Acta Med Scand 1983; 214: 403–7
   PubMedGoogle Scholar
• Edwards R L, Levine J B, Green R, et al. Activation of blood coagulation in Crohn's disease: increased plasma fibrino-peptide A levels and enhanced generation of monocyte tissue factor activity. Gastroenterology 1987; 92: 329–37
   PubMed Web of Science ®Google Scholar
• D'Agostino L, Ciacci C, Daniele B, Barone M V, Sollazzo R, Mazzacca G. Plasma diamine oxidase (DAO) and heparin. Dig DisSci 1984; 29: 1070–1
   PubMedGoogle Scholar
• D'Agostino L, Ciacci C, Daniele B, Barone M V, Sollazzo R, Mazzacca G. Postheparin plasma diamine oxidase in subjects with small bowel mucosal atrophy. Dig Dis Sci 1987; 32: 313–7
   PubMedGoogle Scholar
• D'Agostino L, Daniele B, Pallone F, Pignata S, Leoni M, Mazzacca G. Postheparin plasma diamine oxidase in patients with small bowel Crohn's disease. Gastroenterology 1988; 95: 1503–9
   PubMed Web of Science ®Google Scholar
• Rokkas T, Vaja S, Murphy G M, Dowling RH. Postheparin plasma diamine oxidase in health and intestinal disease. Gastroenterology 1990; 98: 1493–1501
   PubMed Web of Science ®Google Scholar
• D'Agostino L, Pignata S, Daniele B, et al. Postheparin plasma diamine oxidase values in the follow up of patients with small bowel Crohn's disease. Gut 1991; 32: 932–5
   PubMedGoogle Scholar
• Nielsen H, Petersen P H, Feldt-Rasmussen U, Binder V. Variations in plasma proteins concentrations in individuals with ulcerative colitis: analytical and biological factors. Scand J Clin Lab Invest 1979; 39: 495–502
   PubMed Web of Science ®Google Scholar
• Lobo A J, Sobala G M, Juby L D, Jones S C, Rathbone B J, Axon A TR. Evaluation of indices of disease activity in Crohn's disease by consensus analysis. Eur J Gastroenterol Hepatol 1991; 3: 663–6
   Google Scholar
• Reibnegger G, Fuchs D, Judmaier G, Weiss G, Werner-Felmayer G, Wachter H. Critical study of consensus analysis. Lancet 1992; 339: 1394–7
   PubMedGoogle Scholar
• Fretland D J, Djuric S W, Gaginella TS. Eicosanoids and inflammatory bowel disease: regulation and prospects for therapy. Prostagl Leukotr Essent Fatty Acid 1990; 41: 283–301
   Web of Science ®Google Scholar
• Lauritsen K. Drug treatment and formation of eicosanoids in patients with inflammatory bowel disease. Lâgeforeningens forlag, Copenhagen 1989; 1–57
   Google Scholar
• Lauritsen K, Hansen J, Bytzer P, Bukhave K, Rask-Madsen J. Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls. Gut 1984; 25: 1271–8
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Laursen L S, Bukhave K, Rask-Madsen J. In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis. Gut 1987; 28: 1095–9
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Laursen L S, Bukhave K, Rask-Madsen J. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis. Gastroenterology 1988; 95: 11–7
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Laursen L S, Bukhave K, Rask-Madsen J. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986; 91: 837–44
   PubMed Web of Science ®Google Scholar
• Bendixen G, Goltermann N, Jarnum S, Jensen K B, Weeke B, Westergaard H. Immunoglobulin and albumin turnover in ulcerative colitis. Scand J Gastroenterol 1970; 5: 433–41
   PubMed Web of Science ®Google Scholar
• Beeken W L, Busch H J, Sylwester DL. Intestinal protein loss in Crohn's disease. Gastroenterology 1972; 62: 207–15
   PubMed Web of Science ®Google Scholar
• Nordgren S, Hellberg R, Cederblad Å, Fasth S, Lindstedt G, Hultén L. Fecal excretion of radiolabeled (5lCrCl3) proteins in patients with Crohn's disease. Scand J Gastroenterol 1990; 25: 345–51
   PubMed Web of Science ®Google Scholar
• Brignola C, Campieri M, Bazzocchi G, Farruggia P, Tragnone A, Lanfranchi GA. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986; 91: 1490–4
   PubMed Web of Science ®Google Scholar
• Cooke W T, Prior P. Determining disease activity in inflammatory bowel disease. J Clin Gastroenterol 1984; 6: 17–25
   PubMed Web of Science ®Google Scholar
• Burnham W R, Lennard-Jones J E, Hecketsweiler P, Colin R, Geffroy Y. Oral BCG vaccine in Crohn's disease. Gut 1979; 20: 229–33
   PubMedGoogle Scholar
• Bernier J J, Florent C H, Desmazures C H, Aymes C H, L'Hirondel CH. Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin. Lancet 1978; 2: 763–4
   PubMed Web of Science ®Google Scholar
• Karbach U, Ewe K, Bodenstein H. Alpha1-antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn's disease. Gut 1983; 24: 718–23
   PubMed Web of Science ®Google Scholar
• Thomas D W, Sinatra FR. Screening laboratory tests for Crohn's disease. West J Med 1989; 150: 163–4
   PubMedGoogle Scholar
• Meyers S, Wolke A, Field S P, Feuer E J, Johnson J W, Janowitz HD. Fecal α1-antitrypsin measurements: an indicator of Crohn's disease activity. Gastroenterology 1985; 89: 13–8
   PubMed Web of Science ®Google Scholar
• Miura S, Yoshioka M, Tanaka S, et al. Fecal clearance of α1 antitrypsin reflects disease activity and correlates with rapid turnover proteins in chronic inflammatory bowel disease. J Gastroenterol Hepatol 1991; 6: 49–52
   PubMed Web of Science ®Google Scholar
• Crossley J R, Elliot RB. Simple method for diagnosing protein-losing enteropathies. Br Med J 1977; 1: 428–9
   PubMed Web of Science ®Google Scholar
• Boege F, Fischbach W. Structural heterogeneity of faecal α1antitrypsin shown by immunoblast analysis in patients with Crohn's disease. Gut 1991; 32: 496–9
   PubMedGoogle Scholar
• Fischbach W, Becker W, Mössner J, Koch W, Reiners C. Fecal alpha-1-antitrypsin and excretion of 111Indium granulocytes in assessment of disease activity in chronic inflammatory bowel disease. Gut 1987; 28: 386–93
   PubMed Web of Science ®Google Scholar
• Florent C, L'Hirondel C, Desmazures C, Aymes C, Bernier JJ. Intestinal clearance of α1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy. Gastroenterology 1981; 81: 777–80
   PubMed Web of Science ®Google Scholar
• Hollander D. Crohn's disease—a permeability disorder of the tight junction?. Gut 1988; 29: 1621–24
   PubMed Web of Science ®Google Scholar
• Shorter R G, Huizenga K A, Spencer RJ. A working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease. Dig Dis 1972; 17: 1024–31
   Web of Science ®Google Scholar
• Olaison G, Sjödahl R, Tagesson C. Abnormal intestinal permeability in Crohn's disease. A possible pathogenic factor. Scand J Gastroenterol 1990; 25: 321–8
   PubMed Web of Science ®Google Scholar
• Sanderson I R, Boulton P, Menzies I, Walker-Smith JA. Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by elemental diet. Gut 1987; 28: 1073–6
   PubMed Web of Science ®Google Scholar
• Maxton D G, Bjarnason I, Reynolds A P, Catt S D, Peters T J, Menzies IS. Lactulose 51Cr-labelled ethylenediaminetetra-acetate, rhamnose and polyethyleneglycol 500 as probe markers for assessment in vivo human intestinal permeability. Clin. Sci 1986; 71: 71–80
   PubMed Web of Science ®Google Scholar
• O'Morain C A, Abelow A C, Chervu L R, Fleischner G M, Das KM. Chromium 51-ethylenediaminetetraacetate test: a useful test in the assesment of inflammatory bowel disease. J Lab Clin Med 1986; 108: 430–5
   PubMed Web of Science ®Google Scholar
• Bjarnason I, O'Morain C, Levi A J, Peters TJ. Absorption of 51-chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 1983; 85: 318–22
   PubMed Web of Science ®Google Scholar
• Hollander D, Vadheim C M, Brettholz E, Petersen G M, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn's disease and their relatives. Ann Intern. Med 1986; 105: 883–5
   PubMed Web of Science ®Google Scholar
• Ainsworth M, Eriksen J, Rasmussen J W, Schaffalitzky de Muckadell OB. Intestinal permeability of 51Cr-labelled ethylenediaminetetraacetic acid in patients with Crohn's disease and their healthy relatives. Scand J. Gastroenterol 1989; 24: 993–8
   PubMed Web of Science ®Google Scholar
• Ukabam S O, Clamp J R, Cooper BT. Abnormal small intestine permeability to sugars in patients with Crohn's disease of the terminal ileum and colon. Digestion 1983; 27: 70–4
   PubMed Web of Science ®Google Scholar
• Turck D, Ythier H, Maquet E, et al. Intestinal permeability to (51Cr) EDTA in children with Crohn's disease and celiac disease. J Pediatr Gastroenterol Nutr 1987; 6: 535–7
   PubMed Web of Science ®Google Scholar
• Pironi L, Miglioli M, Ruggeri E, et al. Relationship between intestinal permeability to [51Cr]EDTA and inflammatory activity in asymptomatic patients with Crohn's disease. Dig Dis Sci 1990; 35: 582–8
   PubMedGoogle Scholar
• Teahon K, Smethurst P, Pearson M, Levi A J, Bjarnason I. The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. Gastroenterology 1991; 101: 84–9
   PubMed Web of Science ®Google Scholar
• Saverymuttu S H, Peters A M, Hodgson H JF, Chadwick VS. Assessment of disease activity in ulcerative colitis using indium-111-labelled leucocyte faecal excretion. Scand J Gastroenterol 1983; 18: 907–12
   PubMed Web of Science ®Google Scholar
• Segal A W, Ensell J, Munro J M, Sarner M. Indium-111 tagged leucocytes in the diagnosis of inflmmatory bowel disease. Lancet 1981; 2: 230–2
   PubMed Web of Science ®Google Scholar
• Keshavarzian A, Price Y E, Peters A M, Lavender J P, Wright N A, Hodgson H JF. Specificity of indium-111 granulocyte scanning and fecal excretion measurements in inflammatory bowel disease—an autoradiographic study. Dig Dis Sci 1985; 30: 1156–60
   PubMed Web of Science ®Google Scholar
• Schölmerich J, Schmidt E, Schümichen C, Billmann P, Schmidt H, Gerok W. Scintigraphic assessment of bowel involvement and disease activity in Crohn's disease using technetium 99m-hexamethyl propylene amine oxine as leukocyte label. Gastroenterology 1988; 95: 1287–93
   PubMed Web of Science ®Google Scholar
• Park R HR, McKillop J H, Duncan A, Mackenzie J F, Russell RI. Can 111Indium. autologous mixed leucocyte scanning accurately assess disease extent and activity in Crohn's disease?. Gut 1988; 29: 821–5
   PubMedGoogle Scholar
• Leddin D J, Paterson W G, Da Costa L R, et al. Indium-111-labeled autologous leukocyte imaging and fecal excretion. Comparison with conventional methods of assessment of inflammatorv bowel disease. Dig Dis Sci 1987; 32: 377–87
   PubMed Web of Science ®Google Scholar
• Saverymuttu S H, Camilleri M, Rees H, Lavender J P, Hodgson H JF, Chadwick VS. Indium 111-granylocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology and fecal indium 111 granulocyte excretion. Gastroenterology 1986; 90: 1121–8
   PubMed Web of Science ®Google Scholar
• Saverymuttu S H, Peters A M, Lavender J P, Pepys M B, Hodgson H JF, Chadwick VS. Quantitative fecal Indium Ill-labeled leucocyte excretion in the assessment of disease in Crohn's disease. Gastroenterology 1983; 85: 1333–9
   PubMed Web of Science ®Google Scholar
• Pullman W E, Sullivan P J, Barratt P J, Using J, Booth J A, Doe WF. Assessment of inflammatory bowel disease activity by technetium 99m phagocyte scanning. Gastroenterology 1988; 95: 989–96
   PubMed Web of Science ®Google Scholar
• Saverymuttu S H, Peters A M, Lavender J P, Hodgson H J, Chadwick VS. 111Indium autologous leucocytes in inflammatory bowel disease. Gut 1983; 24: 293–9
   PubMed Web of Science ®Google Scholar
• Crama-Bohbouth G, Pena A S, Biemond I, et al. Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease. Gut 1989; 30: 1236–40
   PubMed Web of Science ®Google Scholar
• Wright J P, Alp M N, Young G O, Tigler-Wybrandi N. Predictors of acute relapse of Crohn's disease: a laboratory and clinical study. Dig Dis Sci 1987; 32: 164–70
   PubMed Web of Science ®Google Scholar
• Lanfranchi G A, Brignola C, Tragone A, Farruggia P. Prognostic indices in Crohn's disease. Inflammatory bowel disease: basic research and clinical implications, H Goebell, B M Peskar, H Malchow. MTP, LancasterUK 1988; 259–64
   Google Scholar
• André C, Descos L, Vignal J, Gillon J. C-reactive protein as a predictor of relapse in asymptomatic patients with Crohn's disease. Scott Med J 1983; 28: 26–9
   PubMedGoogle Scholar
• André C, Descos L, Vignal J. C reactive protein level predicts Crohn's disease relapses in quiescent patients [abstract]. Gut 1979; 20: a940
   Google Scholar
• D'Agostine L, Pignata S, Daniele B, et al. Prediction of relapses in patients with Crohn's disease by postheparin plasma diamine oxidase [abstract]. Gastroenterology 1991; 100: a205
   Google Scholar
• Lauritsen K, Laursen L S, Bukhave K, Rask-Madsen J. Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment. Gut 1988; 29: 1316–21
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Laursen L S, Bukhave K, Rask-Madsen J. Inflammatory intermediaries in inflammatory bowel disease. Int J Colored Dis 1989; 4: 75–90
   PubMed Web of Science ®Google Scholar
• Boirivant M, Pallone F, Ciaco A, Leoni M, Fais S, Torsoli A. Usefulness of fecal α1antitrypsin clearance and fecal concentration as early indicator of postoperative asymptomatic recurrence in Crohn's disease. Dig Dis. Sci 1991; 36: 347–52
   PubMed Web of Science ®Google Scholar
• Korelitz BI. An indicator of Crohn's disease activity. A need unfulfilled. J Clin Gastroenterol 1986; 8: 220–62
   PubMed Web of Science ®Google Scholar